ABX advanced biochemical compounds GmbH has acquired TRIMT GmbH for an undisclosed amount. The transaction transfers full ownership of TRIMT’s intellectual property portfolio and ongoing development programs to ABX, which will integrate the acquired assets into its existing operations. TRIMT will cease to operate as an independent entity following the completion of the deal.
TRIMT, an inventor-founded company, focuses on science and data driven pharmaceutical and clinical developments aimed at addressing highly unmet medical needs. Its work is supported by an interdisciplinary board of advisors and a network of academic and clinical collaborations. ABX, a supplier of advanced biochemical compounds, brings established manufacturing and distribution capabilities to the table. The acquisition gives ABX direct control over TRIMT’s unique IP, which spans both short and long term development goals across a diversified selection of therapeutic targets.
For ABX, the purchase is a straightforward expansion of its pipeline. Rather than licensing individual compounds or partnering on specific projects, ABX now owns the entire portfolio outright. This removes the need for future negotiation with TRIMX’s founders and allows ABX to prioritize development timelines internally. TRIMT’s existing collaborations with academic and clinical partners are expected to continue under the new ownership, providing ABX with ready access to specialized research expertise.
The deal also consolidates TRIMT’s operational strengths into a larger corporate structure. TRIMT’s team, known for a creative and communication-driven approach to disruptive innovation, will now operate within ABX’s framework, which is better equipped to handle late-stage development and potential commercialization. For ABX, the acquisition reduces reliance on third-party innovation and secures a proprietary pipeline that can be advanced at the company’s own pace.
With the transaction closed, ABX will begin the process of reviewing TRIMT’s active projects and deciding which programs to prioritize for clinical advancement. The combined entity now holds a broader set of early-stage assets, and the next phase will involve allocating resources toward the most promising candidates while maintaining the scientific rigor that defined TRIMT’s work.